CoChat

Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer

Open access

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

Abstract

Background: Despite growing therapeutic relevance of ERBB2 amplifications in colorectal cancer (CRC), little is known about ERBB2/ERBB3 mutations. We aimed to characterize these subsets of CRC. Methods: We performed a retrospective analysis of 419 CRC patients from MD Anderson (MDACC) and 619 patients from the Nurses' Health Study (NHS)/Health Professionals Follow-Up Study (HPFS) with tissue sequencing, clinicopathologic, mutational, and consensus molecular subtype (CMS) profiles of ERBB2/ERBB3 mutant patients. A third cohort of 1623 CRC patients with ctDNA assays characterized the ctDNA profile of ERBB2 mutants. All statistical tests were two-sided. Results: ERBB2 mutations occurred in 4.1% (95% confidence interval [CI] = 2.4% to 6.4%), 5.8% (95% CI = 4.1% to 8.0%), and 5.1% (95% CI = 4.0% to 6.2%) of MDACC, NHS/HPFS, and ctDNA patients, respectively. ERBB3 mutations occurred in 5.7% (95% CI = 3.7% to 8.4%, 95% CI = 4.0% to 7.8%) of patients in both tissue cohorts. Age, stage, and tumor location were not associated with either mutation. Microsatellite instability (MSI) was associated with ERBB2 (odds ratio [OR] = 5.98, 95% CI = 2.47 to 14.49, P < .001; OR = 5.13, 95% CI = 2.38 to 11.05, P < .001) and ERBB3 mutations (OR = 3.48, 95% CI = 1.51 to 8.02, P = .002; OR = 3.40, 95% CI = 1.05 to 10.96, P = .03) in both tissue cohorts. Neither gene was associated with TP53, APC, KRAS, NRAS, or BRAF mutations in tissue. However, PIK3CA mutations were strongly associated with ERBB2 mutations in all three cohorts (OR = 3.68, 95% CI = 1.83 to 7.41, P = .001; OR = 2.25, 95% CI = 1.11 to 4.58, P = .02; OR = 2.11, 95% CI = 1.25 to 3.58, P = .004) and ERBB3 mutations in the MDACC cohort (OR = 13.26, 95% CI = 5.27 to 33.33, P < .001). ERBB2 (P = 0.08) and ERBB3 (P = .008) mutations were associated with CMS1 subtype. ERBB2 (hazard ratio [HR] = 1.82, 95% CI = 1.23 to 4.03, P = .009), but not ERBB3 (HR = 0.88, 95% CI = 0.45 to 1.73, P = .73), mutations were associated with worse overall survival. Conclusions: MSI and PIK3CA mutations are associated with ERBB2/ERBB3 mutations. Co-occurring PIK3CA mutations may represent a second hit to oncogenic signaling that needs consideration when targeting ERBB2/ERBB3.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djy067

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 1

  1. Sartore-Bianchi, 2016, Dual-targeted therapy with trastuzumab and lapatinib in HER2-positive metastatic colorectal cancer ( HERACLES ): A proof-of-concept, multicentre, open-label, phase 2 trial, Lancet Oncol, 2045, 1

Cited by

See all 78

Metadata

Authors
Loree, J. M., Bailey, A. M., Johnson, A. M., Yu, Y., Wu, W., Bristow, C. A., Davis, J. S., Shaw, K. R., Broaddus, R., Banks, K. C., Lanman, R. B., Meric-Bernstam, F., Overman, M. J., Kopetz, S., & Raghav, K.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Guardant (United States) (US)
  • Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX
Corresponding author
Raghav, Kanwal
Venue
JNCI: Journal of the National Cancer Institute
Published
2018-04-27
Volume
110
Issue
12
Pages
1409-1417
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2799837591
Cited by
68
References
31
Citations by year
2026: 4 · 2025: 9 · 2024: 7 · 2023: 7 · 2022: 15 · 2021: 12 · 2020: 7 · 2019: 5 · 2018: 2
FWCI
2.44
Type
journal article
Language
en
Open access
Locations
  • JNCI Journal of the National Cancer Institute (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • American Society of Clinical Oncology
  • Duncan Family Institute for Cancer Prevention and Risk Assessment
  • National Institutes of Health (CA 172670, CA 187238)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
colorectal cancer, ERBB2 mutations, HER2, HER3, circulating tumor DNA, microsatellite instability, PIK3CA mutation, consensus molecular subtypes, molecular subtypes, tumor suppressor, KRAS, BRAF, APC, TP53, BRAF mutation
MeSH terms
Aged, Exons, Female, Follow-Up Studies, Gene Frequency, Humans, Male, Middle Aged, Mutation, Neoplasm Staging, Prognosis, Retrospective Studies, Biomarkers, Tumor, Colorectal Neoplasms, Proportional Hazards Models, Erb-b2 Receptor Tyrosine Kinases, Genetic Predisposition to Disease, Receptor, ErbB-3, Genetic Association Studies, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. https://app.cochat.ai/papers/10.1093/jnci/djy067
The paper
Loree, J. M., Bailey, A. M., Johnson, A. M., Yu, Y., Wu, W., Bristow, C. A., Davis, J. S., Shaw, K. R., Broaddus, R., Banks, K. C., Lanman, R. B., Meric-Bernstam, F., Overman, M. J., Kopetz, S., & Raghav, K. (2018). Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djy067

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.